• MJHLS Brand Logo

© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

The Top 5 Biosimilar Articles for the Week of August 18

August 22, 2025

Here are the top 5 biosimilar articles for the week of August 18, 2025.

Ten Years of Data Support Safety of Biosimilar Filgrastim for Donor Mobilization

August 22, 2025

Litigation, Launch, and Lower Costs: 3 Big Moves in the US Biosimilar Space

August 19, 2025

The Top 5 Biosimilar Articles for the Week of August 11

August 15, 2025

Denosumab Biosimilar LY01011 Shows Equivalence to Reference Product for Bone Metastases

August 14, 2025

Featured Content

Biosimilar Business Recap: Updates on Tocilizumab, Omalizumab, and Ranibizumab Products

August 13th 2025

By Skylar Jeremias

Article

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ranibizumab.

Japanese Study Provides Postapproval Insights Into Biosimilar Quality Attributes

August 12th 2025

By Skylar Jeremias

Article

Researchers analyze the quality of monoclonal antibody biosimilars in Japan, revealing variations that impact adoption and public confidence in these therapies.

Low Prices Fail to Boost Insulin Biosimilar Uptake in the UK

August 11th 2025

By Skylar Jeremias

Article

Biosimilar insulin glargine struggles for market share in the UK, facing pricing challenges and prescriber inertia despite regulatory support and cost-saving potential.

The Top 5 Biosimilar Articles for the Week of August 4

August 8th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of August 4, 2025.

Dulaglutide Biosimilar LY05008 Shows Efficacy and Safety in Treating Type 2 Diabetes

August 7th 2025

By Cameron Santoro

Article

The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and immunogenicity profiles, to the reference drug dulaglutide in Chinese adults with type 2 diabetes.

Year-Long Phase 3 Study Confirms Tocilizumab Biosimilar Comparability With Actemra

August 6th 2025

By Skylar Jeremias

Article

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis treatment, enhancing access and affordability.

Postmarketing Surveillance Data Reinforce Trastuzumab Biosimilar Safety in HER2+ Gastric Cancer

August 5th 2025

By Deana Ferreri, PhD

Article

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

The Top 5 Biosimilar Articles for the Week of July 28

August 1st 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of July 28, 2025.

Biosimilars News Roundup: July 2025

July 31st 2025

By Skylar Jeremias

Article

Explore the latest biosimilar developments, including legislative changes, new approvals, and challenges in understanding, shaping the future of affordable health care.

Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs

July 30th 2025

By Cameron Santoro

Article

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.